ALX Oncology Holdings Inc. - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 checkpoint pathway. The company's lead product candidate is evorpacept, currently in multiple Phase 1 and 2 clinical trials. A second candidate, ALX2004 (an EGFR-targeted ADC), received FDA clearance for a Phase 1 trial in April 2025. The company has no approved products and has not generated any product revenue.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(30.8) million | $(35.6) million |
| Net Loss Per Share (Basic/Diluted) | $(0.58) | $(0.71) |
| Operating Expenses | $31.8 million | $37.8 million |
| Cash, Cash Equivalents & Investments | $107.0 million | $131.3 million |
| Term Loan Outstanding | $10.0 million | $10.0 million |
| Accumulated Deficit | $(651.9) million | $(521.9) million |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 14% ($4.8 million) compared to Q1 2024, primarily driven by a 25% reduction in Research and Development (R&D) expenses.
- R&D Expense Decline: R&D expenses dropped to $23.9 million from $31.7 million. This was due to a $7.0 million decrease in clinical and development costs (completion of manufacturing for clinical materials in early 2024) and a $2.0 million decrease in stock-based compensation.
- G&A Expense Increase: General and Administrative expenses rose 31% to $7.9 million, driven by a $1.2 million increase in personnel costs related to severance from a workforce reduction.
- Investment Portfolio: Total cash and investments decreased by approximately $24.3 million quarter-over-quarter due to operating cash burn and lower interest income ($1.5 million vs. $2.6 million in prior year).
Guidance, Outlook, and Risks
- Clinical Trial Outcomes:
- Discontinued Programs: The company announced it will no longer pursue evorpacept in combination with pembrolizumab for Head and Neck Squamous Cell Carcinoma (HNSCC) after Phase 2 trials (ASPEN-03 and ASPEN-04) failed to meet primary endpoints. Additionally, the ASPEN-07 trial in urothelial cancer was discontinued as the addition of evorpacept did not meet efficacy bars.
- Regulatory Hurdle: The FDA indicated that ASPEN-06 Phase 2 data in gastric cancer is not eligible for accelerated approval due to the availability of ENHERTU. A Phase 3 trial would be required, which the company will not pursue in the U.S. at this time, opting instead to explore partnerships.
- Positive Data: Updated data from ASPEN-06 (Gastric/GEJ cancer) showed an Overall Response Rate (ORR) of 41.3% for the combination arm vs. 26.6% for control. Positive data was also reported in investigator-sponsored trials for Non-Hodgkin Lymphoma.
- Liquidity and Capital Resources: Management believes existing cash and investments ($107.0 million) are sufficient to fund operations into the fourth quarter of 2026. The company has an At-The-Market (ATM) offering program available and a term loan with $25.0 million available at the lenders' sole discretion.
- Workforce Reduction: The company implemented a reduction in force (RIF) of approximately 30% of employees to prioritize the pipeline and preserve cash. Subsequent severance payments of approximately $1.5 million were made after the quarter-end.
- Nasdaq Compliance Risk: On April 23, 2025, the company received notice from Nasdaq that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has a 180-day compliance period (until October 20, 2025) to regain compliance, potentially via a reverse stock split.
Investor Verification Checklist
- Verify the specific terms and likelihood of securing a development partner for the gastric cancer program given the FDA's feedback on the Phase 3 requirement.
- Monitor the company's stock price to assess the risk of delisting from Nasdaq and the potential impact of a reverse stock split on liquidity.
- Review the burn rate relative to the $107 million cash position to confirm the runway extends to Q4 2026 as projected.
- Assess the impact of the 30% workforce reduction on the timeline for the ALX2004 Phase 1 trial and remaining evorpacept programs.
- Confirm the status of the $25 million discretionary tranche of the term loan and the company's ability to access it if needed.